|Nome||Titolo||Retribuzione||Esercitate||Anno di nascita|
|Mr. David Veitch||Chief Exec. Officer||1,11M||N/D||1965|
|Mr. Adesh Kaul||Chief Financial Officer||N/D||N/D||1974|
|Dr. Gerrit Hauck Ph.D.||Chief Technology Officer||N/D||N/D||1964|
|Dr. Laurenz Kellenberger Ph.D.||Chief Scientific Officer||N/D||N/D||1967|
|Dr. Marc Engelhardt M.D.||Chief Medical Officer||N/D||N/D||1964|
|Dr. Peer Nils Schroder||Head of Corp. Communications & Investor Relations||N/D||N/D||N/D|
|Mr. Damian Heller||Gen. Counsel & Corp. Sec.||N/D||N/D||1966|
|Ms. Ursula Eberhardt||Head of Global HR||N/D||N/D||1962|
|Mr. Lutz Wevelsiep||Head of Regulatory Affairs||N/D||N/D||N/D|
|Mr. Dietrich Stüber||Head of Internal Services||N/D||N/D||N/D|
Basilea Pharmaceutica AG, a commercial stage biopharmaceutical company, focuses on the development of products that address the medical needs in the therapeutic areas of oncology and anti-infectives. It offers Cresemba, an intravenous and oral azole antifungal drug for the treatment of invasive aspergillosis and mucormycosis in the United States, and the European Union, as well as in Phase III clinical trials for invasive fungal infections in Japan. The company also provides Zevtera, an antibiotic for the treatment of community and hospital-acquired pneumonia, as well as in Phase III clinical trials for the treatment of acute bacterial skin and skin structure infections, and Staphylococcus aureus bacteremia. In addition, it engages in developing Derazantinib, a small molecule inhibitor, which is in phase 2 clinical trial for bile duct cancer, as well as in phase ½ clinical trial for bladder and stomach cancer; and Lisavanbulin, a tumor checkpoint controller drug. Basilea Pharmaceutica AG was founded in 2000 and is headquartered in Basel, Switzerland.
L'ISS Governance QualityScore di Basilea Pharmaceutica AG al N/D è N/D. I criteri di valutazione fondamentali sono revisione: N/D; Consiglio di Amministrazione: N/D; diritti degli azionisti: N/D; retribuzione: N/D.